Nisa Investment Advisors, LLC Inhibrx, Inc. Transaction History

Nisa Investment Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	BUY	$32.76 - $39.56 $851 - $1,028	26 Added 1.94%	1,369 $47,000
Q3 2023 Nov 02, 2023	SELL	$15.75 - $26.31 $15,702 - $26,231	-997 Reduced 42.61%	1,343 $24,000
Q2 2023 Aug 11, 2023	BUY	$16.96 - $27.82 $220 - $361	13 Added 0.56%	2,340 $60,000
Q1 2023 May 02, 2023	SELL	$18.45 - $27.14 $350 - $515	-19 Reduced 0.81%	2,327 $44,000
Q3 2022 Nov 07, 2022	BUY	$11.58 - $24.73 $23,461 - $50,102	2,026 Added 633.13%	2,346 $47,000
Q2 2022 Aug 03, 2022	SELL	$8.52 - $25.26 $92,016 - $272,808	-10,800 Reduced 97.12%	320 $4,000
Q1 2022 Apr 29, 2022	BUY	$19.89 - $43.18 $201,286 - $436,981	10,120 Added 1012.0%	11,120 $248,000
Q4 2021 Feb 03, 2022	BUY	$26.75 - $46.02 $26,750 - $46,020	1,000 New	1,000 $27,000

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $565M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Nisa Investment Advisors, LLC with notifications on news.